<DOC>
	<DOC>NCT01092065</DOC>
	<brief_summary>This Phase IIb exploratory study is designed to determine whether AFQ056 is safe and effective and whether it can increase the therapeutic window of L-dopa in patients whose control of their Parkinson's Disease symptoms is limited by the development of dyskinesia induced by use of L-dopa.</brief_summary>
	<brief_title>Efficacy and Safety of AFQ056 When Combined With Increased Doses of L-dopa in Parkinson's Disease Patients With Moderate-severe L-dopa Induced Dyskinesia</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Dyskinesias</mesh_term>
	<mesh_term>Dihydroxyphenylalanine</mesh_term>
	<mesh_term>Levodopa</mesh_term>
	<criteria>Outpatients with Parkinson's Disease (PD), treated with Ldopa, experiencing OFF time and dyskinesias for at least three months Surgical treatment for PD Cancer within the past 5 years (other than localized skin cancer and prostate cancer that has been effectively treated) Advanced, severe or unstable disease (other than PD) that may interfere with the study outcome evaluations Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>Parkinson's Disease</keyword>
	<keyword>Dyskinesia</keyword>
	<keyword>Drug-induced</keyword>
	<keyword>Levodopa</keyword>
	<keyword>L-dopa</keyword>
</DOC>